Organisation paid for research Program year 2025 Source: CMS Open Payments

Scri Oncology Partners

Neither a doctor nor a teaching hospital

Research payments

$1,542,893

444 payments

Through program year 2025, Scri Oncology Partners is reported as receiving $1,542,893 in research payments, across 444 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $1,353,387 406
2024 Research $189,506 38

Breakdown

Who paid Research payments · program years 2024–2025
  1. Merck Sharp & Dohme Corporation $509,156 10 payments
  2. Boehringer Ingelheim Pharma GmbH & Co.KG $475,222 16 payments
  3. Pfizer Inc. $252,418 15 payments
  4. Novartis Pharmaceuticals Corporation $103,683 3 payments
  5. Boehringer Ingelheim International GmbH $73,361 76 payments
  6. AstraZeneca Pharmaceuticals LP $31,750 7 payments
  7. Janssen Research & Development, LLC $30,753 15 payments
  8. Ipsen Pharma SAS $28,957 18 payments
  9. Incyte Corporation $20,030 9 payments
  10. Daiichi Sankyo Inc. $16,129 257 payments
Studies the money was for Research payments · program years 2024–2025
  1. Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) $277,207 72 payments
  2. Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations $270,570 14 payments
  3. A Phase 3 Randomized Openlabel Study of Pf06821497 Mevrometostat in Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel in Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Mevpro1 $200,874 6 payments
  4. A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippel-Lindau VHL Disease-Associate $103,613 1 payment
  5. MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With Next-generation Hormonal Agent NHA $102,965 1 payment
  6. A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 $99,631 1 payment
  7. A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 $83,026 1 payment
  8. A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an "Inclisiran First" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (70 mg/dL) Despite $48,557 1 payment
  9. An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors $47,782 1 payment
  10. An Interventional Phase 3 Doubleblind Randomized Study to Evaluate Efficacy and Safety of Pf08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Locally Advanced Or Metastatic Nonsmall Cell Lung Cancer $47,304 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record